| Susan L Alexander, MD | |
|
710 Home Rd, Delaware, OH 43015-8906 | |
| (330) 329-6414 | |
| Not Available |
| Full Name | Susan L Alexander |
|---|---|
| Gender | Female |
| Speciality | Respite Care - Respite Care, Intellectual And/or Developmental Disabilities, Child |
| Location | 710 Home Rd, Delaware, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720019524 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 35-055243 (Ohio) | Secondary |
| 385HR2060X | Respite Care - Respite Care, Intellectual And/or Developmental Disabilities, Child | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Susan L Alexander, MD 710 Home Rd, Delaware, OH 43015-8906 Ph: (330) 329-6414 | Susan L Alexander, MD 710 Home Rd, Delaware, OH 43015-8906 Ph: (330) 329-6414 |
News Archive
Predicting adult body height from genetic data is helpful in several areas such as pediatric endocrinology and forensic investigations. However, despite large international efforts to catalogue the genes that influence the stature of humans, knowledge on genetic determinants of adult body height is still incomplete. Now DNA-based prediction of taller-than-average body height is feasible, as reported by researchers from the Netherlands and Sweden in an article published in Springer's journal Human Genetics
Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.
CBH is the first hospital in Central Kentucky to perform the transcatheter aortic valve replacement (TAVR) procedure. Four patients with diseased aortic heart valves who were deemed too sick to withstand conventional open-heart surgery to replace their valves have undergone this new heart valve replacement procedure at Central Baptist Hospital.
The OFT has launched a market study into the distribution of medicines in the UK. This decision follows recent and proposed distribution changes by leading UK medicine suppliers.
Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.
› Verified 9 days ago